Zoetis Inc.
Zoetis Inc. (ZTS)
Overview
Zoetis is a Parsippany, New Jersey-headquartered animal health company and the world's largest standalone producer of medicines, vaccines, and diagnostics for pets and livestock. Spun off from Pfizer's Animal Health division and taken public on February 1, 2013 — at the time the largest U.S. IPO since Facebook's 2012 offering, raising roughly $2.2 billion — Zoetis is classified in the Health Care sector under the Pharmaceuticals industry group and trades on the NYSE. The company employs about 14,500 people, operates 28 manufacturing sites across 11 countries, markets directly in roughly 45 countries and sells in over 100, and generates roughly $9.5 billion in annual revenue with a market capitalization in the low-to-mid $30 billions.
What They Do & How They Make Money
Zoetis discovers, develops, manufactures, and sells products that keep animals healthy and, in the case of livestock, productive. On the companion-animal side (dogs, cats, and horses), it sells prescription medicines, vaccines, parasiticides (flea/tick and heartworm prevention), pain management and dermatology treatments, and diagnostic tests and instruments used in veterinary clinics — revenue that scales with pet ownership rates, spending per pet, and the frequency of vet visits. On the livestock side (cattle, swine, poultry, fish, and sheep), it sells vaccines, anti-infectives, and medicated feed additives that help farmers prevent disease outbreaks and improve the health and yield of their herds and flocks — a business tied to global protein demand, farm economics, and the ongoing shift toward more intensive, disease-conscious animal agriculture. Zoetis makes money through a fairly traditional pharmaceutical model: heavy R&D investment to develop and patent new molecules, vaccines, and diagnostic platforms, manufacturing at scale, and then selling through veterinarians, distributors, and (increasingly, for parasiticides in particular) retail and e-commerce channels directly to pet owners. Diagnostics — blood analyzers, test kits, and increasingly genetic and precision-health tools — has become an important second profit engine layered on top of the core pharma/vaccine business, generating recurring instrument and consumable revenue inside vet clinics.
Business Segments
Zoetis organizes its business around two customer-facing categories rather than a large number of formal reporting segments:
- Companion Animal — medicines, vaccines, parasiticides, dermatology treatments (including monoclonal antibody therapies for allergic itch), pain management, and diagnostics for dogs, cats, and horses. This has been the company's primary growth engine in recent years, driven by pet-ownership trends and rising per-pet healthcare spending, though growth has recently slowed as veterinary clinic visit volumes softened.
- Livestock — vaccines, anti-infectives, parasiticides, and medicated feed additives for cattle, swine, poultry, fish, and sheep, a steadier but slower-growing business tied to global food-animal production.
Zoetis also reports results geographically (U.S. versus international operations, with international representing roughly half of total revenue) and by product class — vaccines, anti-infectives, parasiticides, dermatology, other pharmaceutical products, medicated feed additives, and animal health diagnostics. Full-year revenue grew from about $8.08 billion in 2022 to $8.54 billion in 2023 and $9.26 billion in 2024; 2025 revenue came in around $9.4–9.5 billion, a much slower growth rate than prior years, and 2026 guidance has been cut amid flat companion-animal revenue and fewer veterinary clinic visits.
Competitors
- Diversified animal health majors: Elanco Animal Health (spun off from Eli Lilly; the third-largest global animal health company, behind Zoetis), Merck Animal Health (a division of Merck & Co.), and Boehringer Ingelheim Animal Health (privately held)
- Mid-sized global players: Virbac (France) and Ceva Santé Animale (France), both strong in vaccines and companion-animal therapeutics outside the U.S.
- Diagnostics-focused competition: IDEXX Laboratories, the dominant player in veterinary diagnostics and a direct rival to Zoetis's diagnostics unit
- Generic and regional manufacturers that compete on price in off-patent parasiticides and vaccines, particularly in livestock and emerging markets
Competitive Position
Zoetis's competitive advantage rests on being the largest pure-play animal health company by revenue, giving it scale advantages in R&D, manufacturing, and global regulatory/commercial infrastructure that few rivals can match — most competitors are either smaller specialists or animal-health divisions embedded inside larger human-pharma companies (Merck, Boehringer Ingelheim) that don't always prioritize the category. Its product portfolio is broad across both companion animal and livestock, and across therapeutic categories, insulating it somewhat from weakness in any single product line or species. Patents on innovative products (e.g., monoclonal antibody dermatology treatments, novel parasiticides) provide periods of pricing power and exclusivity, while its diagnostics business creates recurring, razor-and-blade-style revenue from instruments placed in vet clinics. Bolt-on acquisitions — Abaxis in 2018 (point-of-care diagnostics), Jurox in 2021, Basepaws in 2022 (pet genetics), and Petmedix in 2023 (antibody-therapeutic technology) — have systematically filled out its diagnostics and next-generation therapeutics capabilities.
The main risks are cyclicality and patent exposure. Zoetis's biggest recent challenge has been a slowdown in companion-animal demand: veterinary clinic visit growth has cooled from its pandemic-era boom, and management has reduced full-year guidance in response, which has weighed heavily on the stock. Key blockbuster products, particularly in parasiticides and dermatology, face eventual patent expiration and generic/biosimilar competition, a standard pharmaceutical risk. Livestock revenue is exposed to farm economics, disease outbreaks (which can cut both ways — driving vaccine demand but also disrupting herds), and trade/tariff policy affecting global protein markets. Zoetis also faces continued competitive pressure from IDEXX in diagnostics, where IDEXX has historically held a stronger clinic-relationship position, and from Elanco and Merck Animal Health, both of which have been consolidating and investing to close the scale gap. Currency risk is meaningful too, given that roughly half of revenue comes from outside the U.S.